AB Announces Publication Of Preclinical Study Results With Masitinib In ALS

(RTTNews) - AB Science SA (AB) announced the publication of preclinical study results with masitinib in amyotrophic lateral sclerosis or ALS.

'These findings demonstrate an unprecedented protective effect for masitinib in ALS rat models with respect to other studies found in the scientific literature' said Professor Luis Barbeito Head of the Neurodegeneration Laboratory, Institut Pasteur in Montevideo, Uruguay.

In particular, masitinib was protective when administered after onset of overt paralysis, a model that closely simulates the clinical condition of ALS patients and therefore better represents their therapeutic needs.

The publication follows the positive interim results of a phase 2/3 study comparing the efficacy and safety of masitinib in combination with riluzole versus placebo in combination with riluzole in the treatment of patients suffering from amyotrophic lateral sclerosis (ALS).